Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Patient-reported cognitive complaints in older adults with gastrointestinal malignancies at diagnosis– Results from the Cancer & Aging Resilience Evaluation (CARE) studyJournal of Geriatric Oncology.  11:982-988. 2020
2020 Oncology practice in the COVID-19 pandemic: A report of a Nigerian expert panel discussion (oncology care in Nigeria during the COVID-19 pandemic)Pan African Medical Journal.  36:1-9. 2020
2020 Systemic treatment for advanced hepatocellular carcinomaJCOM.  27:85-96. 2020
2020 Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE)Journal of Geriatric Oncology.  11:270-273. 2020
2020 Association of malnutrition with geriatric assessment impairments and health-related quality of life among older adults with gastrointestinal malignanciesCancer2020
2020 Vaccine and cell-based therapeutic approaches in acute myeloid leukemiaCurrent Cancer Drug Targets.  20:473-489. 2020
2019 Disparities in clinical outcomes across age, sex and race among patients with pancreatic adenocarcinoma: a single center experienceAnnals of Oncology.  30:iv64. 2019
2019 Efficacy and tolerability of the combination of Liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic cancers: post-approval clinic experienceAnnals of Oncology.  30:iv74. 2019
2019 Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy for patients with locally advanced pancreatic cancerAnnals of Oncology.  30:iv67. 2019
2019 Stereotactic body radiotherapy in locally advanced pancreatic adenocarcinoma: A single institution experienceAnnals of Oncology.  30:iv89. 2019
2019 Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: A retrospective studyBMC Cancer.  19. 2019
2019 Update on systemic therapy for colorectal cancer: Biologics take sidesTranslational gastrointestinal cancer.  4. 2019
2019 Prolonged response to Anti-PD-1 antibody therapy in chemotherapy-refractory cholangiocarcinoma with high tumor mutational burden 2019
2018 Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOXClinical Cancer Research.  24:6204-6211. 2018
2018 A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic CarcinomaJournal of Thoracic Oncology.  13:1940-1948. 2018
2018 Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma 2018
2018 Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic ductal adenocarcinoma patients treated with FOLFIRINOXAnnals of Oncology.  29:viii242. 2018
2017 Immunotherapeutic concepts to target acute myeloid leukemia: Focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironmentInternational Journal of Molecular Sciences.  18. 2017
2017 Locoregional and systemic therapy for hepatocellular carcinomaJournal of Gastrointestinal Oncology.  8:215-228. 2017
2016 The Role of Adjuvant Treatment in Resected T3N0 Rectal CancerCurrent Colorectal Cancer Reports.  12:324-331. 2016
2016 Amplification of TGFβ induced ITGB6 gene transcription may promote pulmonary fibrosisPLoS ONE.  11. 2016
2014 Re: Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer 2014
2005 Road safety practices among commercial motorcyclists in a rural town in Nigeria: Implications for health educationInternational Quarterly of Community Health Education.  24:55-64. 2005

Principal Investigator On

  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2020 - 2025
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2020 - 2025
  • Private Grant  awarded by INCYTE CORPORATION 2019 - 2023
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2019 - 2022
  • Investigator On

  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University 2020 - 2025
  • Private Grant  awarded by ARCUS BIOSCIENCES INC 2020 - 2025
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2020 - 2025
  • Private Grant  awarded by ELI LILLY AND COMPANY 2019 - 2024
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC 2019 - 2024
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2020 - 2024
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC. 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • Private Grant  awarded by MINNEAMRITA THERAPEUTICS, LLC 2018 - 2023
  • Private Grant  awarded by DECIPHERA PHARMACEUTICALS. LLC 2019 - 2023
  • Private Grant  awarded by MIRATI THERAPEUTICS, INC. 2020 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2020 - 2023
  • Private Grant  awarded by BOSTON BIOMEDICAL, INC. 2017 - 2022
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2019 - 2022
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2019
  • Education And Training

  • Master of Science in Immunology, The University of Nottingham 2010
  • Bachelor of Medicine & Surgery (MBBS), University of Ibadan 2006
  • Full Name

  • Olumide Gbolahan